Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Omkar Speciality Chemicals has advanced into pharmaceutical business with the acquisition of LASA Laboratory, which consists of an API manufacturing facility.
Subscribe to our email newsletter
The purchase is expected to allow the company to focus on manufacturing anthelmintics, such as Albendazol EP, Albendazole IP/USP, Cyromazine, Fenbendazole, BP VET / EP, Nitroxynil BP Vet, Ricobendazole, Toldimphos Sodium and Triclabendazole.
The API division will initially focus on continuing the existing API business of LASA laboratory.
Currently, the product portfolio in the division consists of 10 products in the veterinary anthelmentics segment, majorly Benzimidazoles and other active pharma ingredients.